Drugs Made In America Acquisition Corp. Annual Report - How They Did This Year

I am writing this guide to help you understand how Drugs Made In America Acquisition Corp. performed this year. My goal is to cut through the corporate jargon and give you the facts you need to decide if this company fits your portfolio.

1. What does this company do?

This is a "blank check" company, also known as a Special Purpose Acquisition Company (SPAC). It does not make drugs or earn money from business operations. It is a shell company that raised $241 million in its 2024 initial public offering. Its only goal is to find and merge with a private company, taking that business public.

2. Major Leadership Shakeup

In February 2026, the company removed CEO and Chair Lynn Stockwell following reports that a company she controlled faced claims of misusing funds and unpaid debts. The board appointed Roger Bendelac as CEO to rebuild investor trust and find a merger partner. The company confirmed that the $241 million in its trust account remains safe from these legal issues, as those funds are legally restricted to a merger or liquidation.

3. Financial Health and The "Target"

The company is racing to finish a merger before it must return its cash to shareholders.

• The Cash: They hold $241 million in a trust account, which earns interest to pay for daily costs.
• New Funding: To cover legal and audit fees, the company borrowed $500,000 from an affiliate of the sponsor. This loan is interest-free and must be paid back when the merger closes.
• The Potential Deal: They signed a non-binding agreement to buy Power Analytics Global Corp., a firm that builds AI-driven cybersecurity tools. The deal values the firm at about $1 billion. The company is currently evaluating the firm's technology, past sales, and the growth potential of its software business.

4. The Clock is Ticking

SPACs have strict deadlines. The company is asking shareholders to extend its deadline to April 2027. If the merger with Power Analytics fails or shareholders reject the extension, the company must shut down. It would then return the $241 million, plus interest, to shareholders.

5. Key Risks

• Management Uncertainty: New CEO Roger Bendelac faces the task of managing a complex merger while navigating the company’s recent leadership transition.
• The "Deal" Isn't Guaranteed: A non-binding agreement is not a final contract. If the company finds issues at Power Analytics or market conditions worsen, the deal could fall apart.
• Dilution: The $500,000 loan allows the lender to convert the debt into shares at a 35% discount. If the deal closes, this will result in the issuance of more shares, which reduces your ownership percentage of the company.

6. Future Outlook

The company is shifting its focus from pharmaceuticals to the technology sector. Investors should watch for the upcoming shareholder vote and any updates on a final merger agreement. Success depends on whether the board can successfully execute the acquisition of Power Analytics and demonstrate that the company is worth its $1 billion valuation.

Investor Tip: Before making a decision, keep a close eye on the upcoming shareholder vote regarding the deadline extension. Since this is a SPAC, your primary safety net is the $241 million in the trust account, which acts as a floor for your investment if the merger does not go through.